Cargando…

Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells

BACKGROUND: Tamoxifen (TAM) is the eminent first-line drug for endocrine therapy of hormone receptor positive premenopausal breast cancer and reduces the risk of recurrence by ∼50%. However, many patients developed TAM resistance and their diseases recurred. Our previous study on transcriptome profi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Men, Xin, Su, Mengyang, Ma, Jun, Mou, Yueyang, Dai, Penggao, Chen, Chao, Cheng, Xi An
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989118/ https://www.ncbi.nlm.nih.gov/pubmed/33745390 http://dx.doi.org/10.1177/15330338211004916

Ejemplares similares

Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer
por: Men, Xin, et al.
Publicado: (2017)

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: Perez White, Bethany, et al.
Publicado: (2013)

Retraction Note to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: White, Bethany Perez, et al.
Publicado: (2017)

Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma
por: Ng, Kevin Tak-Pan, et al.
Publicado: (2020)

Cytotoxic Activities of Silver Nanoparticles and Silver Ions in Parent and Tamoxifen-Resistant T47D Human Breast Cancer Cells and Their Combination Effects with Tamoxifen against Resistant Cells
por: Ostad, Seyed Naser, et al.
Publicado: (2010)

Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment
por: Wu, Huizhe, et al.
Publicado: (2015)

Synthesis of novel 1,8-acridinediones derivatives: Investigation of MDR reversibility on breast cancer cell lines T47D and tamoxifen-resistant T47D
por: Moallem, S.A., et al.
Publicado: (2015)

Overexpression of TMEM158 contributes to ovarian carcinogenesis
por: Cheng, Zhongping, et al.
Publicado: (2015)

Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression
por: Raha, Paromita, et al.
Publicado: (2015)

Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR Signaling
por: Zhang, Xi, et al.
Publicado: (2013)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

The effect of Tmem135 overexpression on the mouse heart
por: Lewis, Sarah Aileen, et al.
Publicado: (2018)

Network-based method for drug target discovery at the isoform level
por: Ma, Jun, et al.
Publicado: (2019)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

A Comparative Study of Cluster Detection Algorithms in Protein–Protein Interaction for Drug Target Discovery and Drug Repurposing
por: Ma, Jun, et al.
Publicado: (2019)

Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape
por: Ben, Xin-Yu, et al.
Publicado: (2022)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer
por: Sun, Xi, et al.
Publicado: (2021)

Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1
por: Hiscox, S, et al.
Publicado: (2008)

COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR
por: Lu, Renquan, et al.
Publicado: (2016)

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2019)

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2022)

Glioma angiogenesis is boosted by ELK3 activating the HIF-1[Formula: see text] /VEGF-A signaling axis
por: Yueyang, Mou, et al.
Publicado: (2023)

An epigenomic approach to therapy for tamoxifen-resistant breast cancer
por: Feng, Qin, et al.
Publicado: (2014)

Molecular mechanisms and mode of tamoxifen resistance in breast cancer
por: Ali, Shazia, et al.
Publicado: (2016)

Association of tamoxifen resistance and lipid reprogramming in breast cancer
por: Hultsch, Susanne, et al.
Publicado: (2018)

Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer
por: Abdel-Hafiz, Hany A.
Publicado: (2017)

Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
por: Yao, Jingwei, et al.
Publicado: (2020)

Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
por: Bekele, Raie T., et al.
Publicado: (2016)

TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma
por: Shi, Ke, et al.
Publicado: (2023)

PKM2–c-Myc–Survivin Cascade Regulates the Cell Proliferation, Migration, and Tamoxifen Resistance in Breast Cancer
por: Yu, Pian, et al.
Publicado: (2020)

Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF−7/SC Breast Cancer Cells
por: To, Ngoc Bao, et al.
Publicado: (2022)

LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer
por: Zhang, Hongkai, et al.
Publicado: (2020)

Drug Efflux Transporters Are Overexpressed in Short-Term Tamoxifen-Induced MCF7 Breast Cancer Cells
por: Krisnamurti, Desak Gede Budi, et al.
Publicado: (2016)

Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells
por: Wang, Lingling, et al.
Publicado: (2021)

Development and characterization of a tamoxifen-resistant breast carcinoma xenograft
por: Naundorf, H, et al.
Publicado: (2000)

Sox2 promotes tamoxifen resistance in breast cancer cells
por: Piva, Marco, et al.
Publicado: (2014)

The role of Nanog expression in tamoxifen-resistant breast cancer cells
por: Arif, Khalid, et al.
Publicado: (2015)

TROP2 methylation and expression in tamoxifen-resistant breast cancer
por: Zimmers, Stephanie M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h6rkruevjrv82n8vmcmcojopj0